Enrollment currently scheduled to begin in Q1 2026 M107 is the first potential disease-modifying drug for the treatment of gastroparesis M107’s mechanism of action has been shown to shift ...

RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics, and its subsidiary, Aclipse Two, Inc (“Aclipse”), an innovative biopharmaceutical company developing life-changing treatments for patients with ...

RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics and its subsidiary Aclipse One Inc (“Aclipse” or “the Company”), an innovative biopharmaceutical company, today announced that the Company has ...

KING OF PRUSSIA, PA — Aclipse Therapeutics has entered a clinical collaboration with Mayo Clinic to advance a Phase 2 study of M107, a novel small-molecule drug positioned as the first potential ...

Chong Kun Dang said on the 27th that its global partner, Aclipse Therapeutics, signed an agreement with the Mayo Clinic for a phase 2 clinical trial of the gastroparesis treatment candidate "M107 ...

KING OF PRUSSIA, Pa., November 17, 2025--(BUSINESS WIRE)--Aclipse Therapeutics LLC ("Aclipse" or "the Company") today announced that it has entered into a clinical collaboration and Know-How Agreement ...

Chong Kun Dang announced on the 27th that its global license partner for the novel diabetes drug lobeglitazone (brand name Duvie), Aclipse Therapeutics, has signed an agreement with the Mayo Clinic in ...

Company to advance M107 into Phase 2 clinical development in gastroparesis based on feedback from Pre-IND meeting with FDA RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics, and its subsidiary, ...